<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832713</url>
  </required_header>
  <id_info>
    <org_study_id>6122</org_study_id>
    <nct_id>NCT02832713</nct_id>
  </id_info>
  <brief_title>Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection for the Treatment of Painful Knee Osteoarthritis</brief_title>
  <acronym>GOTOX</acronym>
  <official_title>Randomized Controlled Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection for the Treatment of Painful Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, osteoarthritis affects about 10 million people and knee osteoarthritis represents&#xD;
      35% of cases. It is thought that more than 2.5 million people older than 65 years have knee&#xD;
      osteoarthritis.&#xD;
&#xD;
      Currently, osteoarthritis management is based on three major axes:&#xD;
&#xD;
        1. Non-pharmacological means, such as patient education, loss of weight and physical&#xD;
           activity&#xD;
&#xD;
        2. General pharmacological treatments: mainly paracetamol and then schedule II and III&#xD;
           painkillers as well as nonsteroidal anti-inflammatory agent.&#xD;
&#xD;
        3. Intra-articular pharmacological treatments:&#xD;
&#xD;
             1. Intra-articular injections of corticosteroids: they are recommended during&#xD;
                hydarthrotic flare-ups&#xD;
&#xD;
             2. Intra-articular injections of hyaluronic acid (HA) (viscosupplementation) in the&#xD;
                absence of intra-articular effusion. However, their efficacy is questioned by most&#xD;
                experts in the case of symptomatic knee osteoarthrosis.&#xD;
&#xD;
        4. Sometimes, surgery is the only therapeutic option. However, besides the fact of exposing&#xD;
           patients, who are sometimes frail, to several peri- and post-operative complications,&#xD;
           the recovery rate (variable according to the prosthesis type and ranging from 5% to 25%&#xD;
           at 9 years) in an ageing population justifies waiting as much as possible before&#xD;
           surgery. Therefore, it is important to test new therapeutic options for symptomatic&#xD;
           osteoarthrosis that will allow postponing the surgical treatment.&#xD;
&#xD;
        5. The use of botulinum toxin (BoNT-A) could thus represents an interesting alternative.&#xD;
           BoNT-A is habitually used by intra-muscular injection for its myorelaxant effect in the&#xD;
           management of painful reactive periarticular muscle contractures. However, BoNT-A has&#xD;
           also antalgic activity independently of the myorelaxant effect. This allows explaining&#xD;
           in part the antalgic effect of intra-articular BoNT-A injection. In the literature, six&#xD;
           randomized controlled studies (RCS) have compared BoNT-A and intra-articular injections&#xD;
           of corticosteroids, hyaluronic acid, or placebo. Only two RCS concerned knee&#xD;
           osteoarthritis and compared BoNT-A to corticosteroids and a placebo, respectively, with&#xD;
           a significant antalgic effect only in the groups treated with BoNT-A. No study has&#xD;
           compared yet the intra-articular injection of BoNT-A to the viscosupplementation by HA&#xD;
           in knee osteoarthritis and this is the aim of this trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of pain measured using the WOMAC pain sub-score</measure>
    <time_frame>Change from baseline WOMAC pain sub-score at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the antalgic effect of BoNT-A vs hyaluronic acid measured using a verbal rating scale (VRS)</measure>
    <time_frame>1 week after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the patients' functional improvement based on the WOMAC score (&quot;stiffness and function sub-score&quot; and total score)</measure>
    <time_frame>Before injection, 1 month, 3 months and 6 months following injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the patients' functional improvement using the Timed Up-and-go Test</measure>
    <time_frame>Before injection, 1 month, 3 months and 6 months following injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the quality of life based on the SF-36 score</measure>
    <time_frame>Before injection, 1 month, 3 months and 6 months following injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, seriousness and severity of adverse event reactions</measure>
    <time_frame>during the 6 months following injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain treatment score (using a correspondence table)</measure>
    <time_frame>Change from baseline pain treatment score at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in muscular strenght et muscular trophicity (using dynanometer and measure of knee and thin circumference)</measure>
    <time_frame>Before injection, 1 month, 3 months and 6 months following injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in passive and active articular knee amplitude, by goniometry</measure>
    <time_frame>Before injection, 1 month, 3 months and 6 months following injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Painful Unilateral Femorotibial Knee Osteoarthritis of Any Etiology</condition>
  <arm_group>
    <arm_group_label>Intra-articular injection of botulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-articular injection of hyaluronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A ( BoNT-A)</intervention_name>
    <description>Intra-articular injection of BoNT-A</description>
    <arm_group_label>Intra-articular injection of botulinum toxin A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid (HA)</intervention_name>
    <description>Intra-articular injection of Hyaluronic acid</description>
    <arm_group_label>Intra-articular injection of hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Painful, or predominantly unilateral painful, knee osteoarthritis of any etiology&#xD;
&#xD;
          -  Knee without clinical signs of intra-articular effusion&#xD;
&#xD;
          -  Kellgren score ≥ II on X-ray&#xD;
&#xD;
          -  WOMAC pain sub-score ≥ 5 in the month preceding the inclusion visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical:&#xD;
&#xD;
          -  Inflammatory arthropathy,infectious, neoplastic within the past year&#xD;
&#xD;
          -  Neuromuscular pathology&#xD;
&#xD;
          -  Cardiorespiratory pathology or any other severe disease that interferes with the&#xD;
             functional capacities&#xD;
&#xD;
          -  Any decompensated or unstable chronic pathology&#xD;
&#xD;
          -  Glomerular filtration rate (GFR)&lt;15 mL/min/1.73m²) within the past 6 months&#xD;
&#xD;
          -  HBA1c in diabetic people &gt; 12% within the past 6 months&#xD;
&#xD;
          -  BMI ≥ 35kg/m2&#xD;
&#xD;
          -  Infection: joint, general, distant, cutaneous&#xD;
&#xD;
          -  Foreign material in the knee to be treated: prosthesis, osteosynthesis material&#xD;
&#xD;
          -  Severe coagulation problem: platelets &lt;100000/mm3 within the past 6 months&#xD;
&#xD;
          -  Allergy to BoNT-A&#xD;
&#xD;
          -  Allergy to HA&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Treatment with aminoglycosides or direct oral anticoagulants&#xD;
&#xD;
          -  Treatment with VKA (antihemorrhagic vitamin) if INR (International Normalized Ratio)&#xD;
             higher than 3 within the past month&#xD;
&#xD;
          -  Change of anti-pain treatment less than 2 weeks before enrolment&#xD;
&#xD;
          -  Treatment with III pain killers or corticosteroids because of intense pain that does&#xD;
             not respond to schedule I and II pain-killers&#xD;
&#xD;
          -  Intra-articular injection of corticosteroids in the previous two months&#xD;
&#xD;
          -  Viscosupplementation and/or injection of BoNT-A in the knee to be treated within the&#xD;
             past 6 months&#xD;
&#xD;
          -  Injection of BoNT-A (except the knee to be treated) within the past 3 months&#xD;
&#xD;
          -  Swallowing troubles&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee osteoarthritis</keyword>
  <keyword>Intra-articular botulinum toxin</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Pain</keyword>
  <keyword>Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

